

APPLICANTS: Edgar, et al.
SERIAL NUMBER: 10/728,340

REMARKS


Claims 1-6 and 13-20 are pending. Claims 1, 6, and 13-20 have been amended. Support for the amendments can be found at least in the specification as originally filed on pages 53-57. Accordingly, no new matter has been added by these amendments. Applicants reserve the right to pursue canceled subject matter in subsequent applications.

35 U.S.C. 112, First Paragraph

The Examiner has rejected claims 1-5, 13-15, and 17-20 under 35 U.S.C. 112, first paragraph as failing to comply with the written description requirement. Claims 6 and 16 are objected to as being dependent upon a rejected base claim, but the Examiner states the claims would be allowable if rewritten. The claims have been amended herein to specify that the alkylene spacer molecule is substituted with a cyclic alkyl or a heterocycle, wherein one or more of the carbons of the spacer molecule is contained in the cyclic alkyl or heterocycle. Applicants submit that the amended claims comply with the written description requirement. Therefore, the rejection is moot and should be withdrawn.

CONCLUSION

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that the pending claims are in condition for allowance.

Respectfully submitted,

for, Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicant
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel.: (617) 542 6000
Fax: (617) 542-2241
Customer No. 30623